UPDATE
: 2021.2.26 ±Ý 06:41
WITH ¸ÞµðÄ«¿î½½(MCIL) ¹Ìµð¾î ¿¬±¸¼Ò
óÀ½À¸·Î
·Î±×ÀÎ
ȸ¿ø°¡ÀÔ
Medi Academy Archive
Clinical Selection
Medi Treat & Law
M Channel Archive
Medi
Pharmacy
Observation
Policy
Global
Opinion
Issue
¸ÞµðÄ«¿î½½(MCIL)
±¸µ¶½Åû
Àüü±â»çº¸±â
¸ð¹ÙÀÏÀ¥
»ó´Ü¿©¹é
񃯇
(Àüü 928°Ç)
Á¦¸ñº¸±â
Á¦¸ñº¸±â
Á¦¸ñ+³»¿ë
¹Ì CDC ±¹Àå "¸¶½ºÅ© Àǹ«È ÇØÁ¦´Â ½Ã±â»óÁ¶"
"Ä¡¸ÅȯÀÚ Äڷγª¿¡ °É¸± È®·ü µÎ ¹è ³ô¾Æ"-Ú¸¿¬±¸Áø
ÈÀÌÀÚ ¹é½Å, ¿µ±¹¼ ¹ß°ßµÈ º¯Á¾ Äڷγª¿¡ 'È¿°ú'
"¿ÃÇØ ¹ÙÀÌ·¯½º º¯ÀÌ ´õ¿í ¸¹¾ÆÁú °Í"-³²¾Æ°ø Àü¹®°¡
Àü ¼¼°è Äڷγª ¹é½Å Á¢Á¾ÀÚ 1000¸¸¸í ³Ñ¾î¼
¶óÀÎ
Àü¼¼°è 40¿©°³±¹ 'º¯ÀÌ ¹ÙÀÌ·¯½º ÃâÇö' ¿µ±¹ ¿©ÇàÁ¦ÇÑ
¾Ëº¸Á¨ÄÚ¸®¾Æ ¸Ó½Ã·Ð, '°ø½Ä À¥»çÀÌÆ® ¸®´º¾ó' ¿ÀÇ¡¦Á÷°üÀû ¸Þ´º¿Í ¼¼·ÎÇü ´ÜÀÏ ÆäÀÌÁö ±¸¼ºÀ¸·Î Á¤º¸ Á¢±Ù¼º °È
´ë¿õÁ¦¾à '¿Ã·Î½ºÅ¸' ¿ì¼öÇÑ È¿°ú¡¤µ¶º¸Àû ±â¼ú·Â ÁÖ¸ñ¡¦Æ¯Çã Ç÷§Æû ±â¼ú '¹æÃâ ¼Óµµ Á¶Àý ÀÌÃþÁ¤' Á¦Çü Á¢¸ñÀ¸·Î ü³» ¾à¹° Èí¼ö ÃÖÀûÈ
Takeda Announces U.S. FDA Breakthrough Therapy Designation Granted for Pevonedistat for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes(HR-MDS)
Takeda Provides Updates on Its Pharmacokinetic-guided Prophylaxis Studies at ISTH 2020, Reinforcing Its Commitment to Advancing Personalized Care for People with Bleeding Disorders
¶óÀÎ
Takeda Provides Updates on its Hemophilia Studies at WFH 2020, Reinforcing its Commitment to Putting Patients First and Supporting Personalized Care for People with Bleeding Disorders
Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO(ixazomib) in Multiple Myeloma as a First-Line Maintenance Therapy
New Data from the Phase 3 HELP Study Open-Label Extension Evaluate the Long-Term Safety and Efficacy of TAKHZYRO? (lanadelumab) in Reducing Hereditary Angioedema Attacks
Takeda to Present Data from the ICLUSIG? (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML
GSK Çѱ¹¹ýÀÎ, Country Medical Director¿¡ ±è¶Ê¹Ì´Ô ¼±ÀÓ
¶óÀÎ
Takeda Announces U.S. FDA Breakthrough Therapy Designation for Mobocertinib(TAK-788) for the Treatment of NSCLC Patients with EGFR Exon 20 Insertion Mutations
European Commission Approves Subcutaneous Formulation of Entyvio? (Vedolizumab) for use as Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis or Crohn¡¯s Disease
European Commission Approves Takeda¡¯s ALUNBRIG? (brigatinib) as a First-Line Treatment for ALK+ NSCLC
ViiV Healthcare Announces First Global Regulatory Approval of CABENUVA; the First Complete, Long-acting, Regimen for the Treatment of HIV
U.S. FDA grants Fast Track designation to empagliflozin for the treatment of chronic kidney disease
-
1
2
3
4
5
6
7
8
9
10
´ÙÀ½
-
Back to Top